GMPS
GMP synthase [glutamine-hydrolyzing]
Protein Summary
Involved in the de novo synthesis of guanine nucleotides which are not only essential for DNA and RNA synthesis, but also provide GTP, which is involved in a number of cellular processes important for cell division. In the de novo synthesis of purine nucleotides, IMP is the branch point metabolite at which point the pathway diverges to the synthesis of either guanine or adenine nucleotides. In the guanine nucleotide pathway, there are 2 enzymes involved in converting IMP to GMP, namely IMP dehydrogenase (IMPD1), which catalyzes the oxidation of IMP to XMP, and GMP synthetase, which catalyzes the amination of XMP to GMP. [provided by RefSeq, Jul 2008]
- ENST00000295920
- ENSP00000295920
- ENSG00000163655
- ENST00000496455
- ENSP00000419851
- GATD7
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
interacting protein | 1 | ||
molecular function | 0.96 | ||
protein domain | 0.92 | ||
transcription factor perturbation | 0.84 | ||
disease perturbation | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 203.99 (req: < 5)
Gene RIFs: 9 (req: <= 3)
Antibodies: 239 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 203.99 (req: >= 5)
Gene RIFs: 9 (req: > 3)
Antibodies: 239 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0